Yun H, et al. Do Patients with Moderate or High Disease Activity Escalate RA Therapy According to Treat-to-Target Principles? Results from the ACR’s RISE Registry. ACR 2018, abstract 2856.
Olokizumab plus methotrexaat: veiligheid en effectiviteit op de lange termijn
dec 2024 | RA